WuXi AppTec boosts U.S. footprint with expanded New Jersey lab site

WuXi AppTec's ribbon cutting ceremony. (PRNewsfoto/WuXi AppTec)

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division (LTD) in New Jersey as it looks to boost its integrated testing service portfolio.

The big reveal this week, attended by State Senator Linda Greenstein, sees its existing site doubled, with total operation space swelling to more than 115,000 square feet and 200 jobs on the books.

After the expansion, LTD’s combined New Jersey operations will be “one of the largest labs for preclinical and clinical drug development testing in the United States,” the Shanghai-based company said in a statement.

Featured Webinar

How to Streamline Your Clinical Research Organization's Processes End to End

Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall trial costs, leave behind spreadsheets and home-grown tools for a predictable trial and the ability to forecast unit delivery resulting in the optics you need to ensure a successful trial, and hear experts share industry trends of what is affecting the Clinical Research Organization industry today.

The site is set up as a new “center of excellence” for drug development, strengthening the China company’s presence in the U.S. and expanding services to biopharma. WuXi says it will also “recruit extensively from the local talent base,” further boosting New Jersey’s life science credentials.

Dr. Jason Liu, SVP of WuXi AppTec and COO of the LTD, said: “The Garden State continues to be an important life science hub. This expansion will allow our team to deliver high quality service with faster turnaround times, better leverage the resources and expertise of the local pharmaceutical and biotechnology community, and develop a stronger connection with our customers.”

WuXi also has sites across several other U.S. states, as well as in its native China, Germany, Israel, South Korea and Japan.

Suggested Articles

A patient has died in the global study of AstraZeneca’s COVID-19 vaccine, Brazil’s health authority, Anvisa, announced on Wednesday.

MyoKardia wasn’t looking for a buyout when it started discussing potential partnerships with Bristol Myers Squibb last year.

Stanford University and its school of medicine have launched plans to survey the population of greater San Francisco for COVID-19.